Non-Billable / Non-Specific Code
ICD-10-CM Z51.1 is the diagnosis code for Encounter for antineoplastic chemotherapy and immunotherapy. This code falls under the section "Encounters for other specific health care" within Chapter 21 â Factors influencing health status and contact with health services (Z00-Z99). It is a non-billable/non-specific ICD-10-CM code that should not be used for reimbursement. A more specific sub-code is required for billing. Medical coders and healthcare providers use this code to document and classify diagnoses in electronic health records, insurance claims, and clinical databases.
The following conditions are not included in Z51.1. If the patient has both, code each condition separately:
Understanding where Z51.1 sits in the ICD-10-CM classification helps ensure proper coding:
No, Z51.1 is a non-billable/non-specific code. You should use a more specific sub-code for billing and reimbursement.
Z51.1 is the ICD-10-CM diagnosis code for "Encounter for antineoplastic chemotherapy and immunotherapy". It is used by healthcare providers to classify and document this condition in medical records and insurance claims.
The parent code of Z51.1 is Z51 ("Encounter for other aftercare and medical care"). Z51.1 provides a more specific classification within this category.
Z51.1 is located in Section Z40-Z53 â "Encounters for other specific health care" within Chapter 21 of the ICD-10-CM Tabular List.
Z51.1 has 2 sub-code(s) that provide more specific detail: Z51.11, Z51.12.
Use Z51.1 when the patients documented diagnosis matches "Encounter for antineoplastic chemotherapy and immunotherapy" and the clinical documentation supports this level of specificity. Always verify with the latest ICD-10-CM guidelines and payer requirements.
The ICD-10-CM code for Encounter for antineoplastic chemotherapy and immunotherapy is Z51.1.
No, Z51.1 is non-billable. Use a more specific sub-code for primary diagnosis billing.
Z51.1 is in Chapter 21 of the ICD-10-CM Tabular List.
Yes, Z51.1 is a valid ICD-10-CM code for the 2026 fiscal year, subject to official CMS updates.